

## AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 109, line 14 as follows:

**Table 3**  
**Exemplary Cells Useful In The Invention**

Cells	Source
Vero E6	ATCC # CRL-1586 DHI # 67-0102
MRC-5	ATCC # CCL-171 DHI # 51-0102
BHK-21	ATCC # CCL-10 DHI # 89-0102
MDCK	ATCC # CCL-34 DHI # 83-0102
HRT-18 (HCT-18)	ATCC # CCL-244
Mv1Lu (NBL-7)	ATCC # CCL-64 DHI # 58-0102
Mv1Lu-hF	ATCC # PTA-4737
CMT-93	ATCC # CCL-223
AK-D	ATCC # CCL-150
A549	ATCC # CCL-185 DHI # 56-0102
HEL	DHI # 88-0102
pRHMK	DHI # 49-T025 DHI # 49-0102
pCMK	DHI # 47-T025 DHI # 47-0102
L2	ATCC # CCL-149
R-Mix	DHI # 96-T025
HEK-293	ATCC #CRL-1573; Graham et al., J Gen Virol, 36 :59-74 (1977)
HEK-293T	Pear, et al., PNAS USA, 90:8392-8396 (1993) ATCC by request of Michele Calos (Stanford University) Interlab Cell Line Collection (ICLC) # ICLC0 #HTL04001 DuBridge et al., Mol. Cell. Biol. 7:379-387 (1987)
Huh-7 (JTC-39)	Japanese Collection of Research Bioresources Cellbank # JCRB0403 Nakabayashi et al., Cancer Res, 42 :3858-63 (1982)